Literature DB >> 10168357

Methods to objectify reversibility of glaucomatous cupping.

A Azuara-Blanco1, G L Spaeth.   

Abstract

Lowering intraocular pressure in adults with glaucoma may be associated with an improvement in appearance of the optic nerve head. The stage of disease, the amount of intraocular pressure reduction, and the age of the patient probably influence the occurrence of this event. The clinical relevance of "reversal" has not been established with certainty. The reversibility of glaucomatous cupping can be detected by subjective and qualitative means (examination of the patient or of fundus photographs) or by quantitative techniques such as photogrammetry, computerized image analysis, and scanning laser tomography. Clinical and experimental studies are providing new information about the behavior of the optic nerve head tissues in response to changes in intraocular pressure.

Entities:  

Mesh:

Year:  1997        PMID: 10168357     DOI: 10.1097/00055735-199704000-00009

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  4 in total

1.  Age related compliance of the lamina cribrosa in human eyes.

Authors:  J Albon; P P Purslow; W S Karwatowski; D L Easty
Journal:  Br J Ophthalmol       Date:  2000-03       Impact factor: 4.638

2.  Optic disc changes following trabeculectomy: longitudinal and localisation of change.

Authors:  A Kotecha; D Siriwardena; F W Fitzke; R A Hitchings; P T Khaw
Journal:  Br J Ophthalmol       Date:  2001-08       Impact factor: 4.638

3.  Disc photography and Heidelberg retinal tomography documentation of reversal of cupping following trabeculectomy.

Authors:  Darana Yuen; Yvonne M Buys
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-06-08       Impact factor: 3.117

4.  Filtration procedures supplemented with mitomycin C in the management of childhood glaucoma.

Authors:  A Azuara-Blanco; R P Wilson; G L Spaeth; C M Schmidt; J J Augsburger
Journal:  Br J Ophthalmol       Date:  1999-02       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.